Keyword Search
 
2017 | 2016
  • PharmAthene Reports Year-End 2016 Financial and Operational Results
  • March 14, 2017 - ANNAPOLIS, Md., March 14, 2017 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and operational results for the year ended December 31, 2016.Fourth quarter and subsequent operational highlights include:On November 16, PharmAthene received a final payment from SIGA Technologies, Inc. which fully satisfied the judgment owed to PharmAthene. In total, the Company received payments of approximately... 
  • PharmAthene Announces Record Date and Meeting Date for Special Meeting of Stockholders Regarding Proposed Merger Transaction with Altimmune
  • March 13, 2017 - ANNAPOLIS, Md., March 13, 2017 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, announced today that it has established a record date and meeting date for a special meeting of stockholders to vote upon, among other things, the proposal to adopt the agreement and plan of merger and reorganization involving PharmAthene and Altimmune, Inc. PharmAthene stockholders of record at the close of business on March 22, 2017, wi... 
  • PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases
  • January 19, 2017 - ANNAPOLIS, Md. and GAITHERSBURG, Md., Jan. 19, 2017 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, announced today the signing of a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Altimmune's current investors include Novartis Venture Fund, HealthCap, Truffle Capital and Redmont Capital. The combined company will be a fully-integrated and diversifi... 
  • PharmAthene Declares $2.91 Special Cash Dividend on Common Stock
  • November 17, 2016 - Final Payment of $83.9 Million Received from SIGA of $217 Million Total JudgmentANNAPOLIS, Md., Nov. 17, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced that its Board of Directors has declared a special one-time cash dividend of $2.91 per share of common stock, payable on February 3, 2017 to holders of record as of January 24, 2017. The special dividend, totaling an aggregate payment of approxi... 
  • PharmAthene Receives Final Payment from SIGA of $83.9 Million
  • November 16, 2016 - - Award amount totals $217 million -ANNAPOLIS, Md., Nov. 16, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today received a final payment from SIGA Technologies, Inc. of $83.9 million which fully satisfies the judgment owed to PharmAthene. In total, PharmAthene has received payment of approximately $217 million including interest from SIGA.Barring any unexpected material events, PharmAthene intends to distrib... 
  • PharmAthene Reports Third Quarter 2016 Financial and Operational Results
  • November 04, 2016 - ANNAPOLIS, Md., Nov. 4, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and operational results for the third quarter of 2016.  PharmAthene received $122.5 million from SIGA Technologies, Inc. during the nine months ended September 30, 2016, comprised of principle payments of $115 million (which amount is creditable against final satisfaction of the judgment in PharmAthene... 
  • PharmAthene Announces Receipt of Payments from SIGA
  • September 16, 2016 - ANNAPOLIS, Md., Sept. 16, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced it has received a series of payments from SIGA Technologies, Inc. totaling $90 million over the past month.  Combined with $25 million in previous payments, PharmAthene has now received a total of $115 million plus $6.6 million of interest in partial payment of the SIGA judgement. Under the approved reorganization plan, SI... 
  • PharmAthene Withdraws Protest Against HHS Over Anthrax Vaccine Bidding Process
  • August 25, 2016 - ANNAPOLIS, Md., Aug. 25, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced that after discussions with the Biomedical Advanced Research and Development Authority (BARDA) the Company has withdrawn the protest filed on August 5, 2016.About PharmAthene PharmAthene is a biodefense company engaged in the development of next generation medical countermeasures against biological threats. The Company's develop... 
  • PharmAthene Files Protest Against HHS Over Anthrax Vaccine Bidding Process
  • August 05, 2016 - ANNAPOLIS, Md., Aug. 5, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today filed a formal protest against the Department of Health and Human Services, challenging its solicitation for a next-generation Anthrax vaccine provider.According to the protest, filed with the U.S. Government Accountability Office, the government's "Request for Proposals" was written in a way that eliminates competition and assures a sole ... 
  • PharmAthene Reports Second Quarter 2016 Financial and Operational Results
  • August 04, 2016 - ANNAPOLIS, Md., Aug. 4, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today reported its financial and operational results for the second quarter of 2016.  Under SIGA's Reorganization Plan, approved by U.S. Bankruptcy Court for the Southern District of New York, PharmAthene received from SIGA an initial payment of $5 million in April 2016, and an aggregate of $3.9 million in payments calculated as interest on... 
  • PharmAthene Receives $20 Million Payment from SIGA to Extend Payment Deadline
  • July 08, 2016 - ANNAPOLIS, Md., July 8, 2016 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, today announced that it has received a $20 million payment from SIGA Technologies, Inc. to extend by 90 days, until October 19, 2016, the date by which SIGA must satisfy the PharmAthene judgment. The payment, made pursuant to the SIGA Bankruptcy Reorganization Plan approved by U.S. Bankruptcy Court for the Southern District of New York effe... 

    © 2017 Altimmune, Inc.   All rights reserved.   Terms of Use